Occam was founded to develop more bioavailable forms of approved drugs, using non-covalent derivatization (“NCD”) technology developed by the Warner Babcock Institute for Green Chemistry (“WBI”). Elm Street Ventures co-founded Occam Sciences with WBI in October, 2011 and provided seed financing. Occam Sciences targeted three approved drugs currently available only in i.v. form, seeking to develop oral forms of these drugs. Elm Street Ventures partner Rob Bettigole served as the initial CEO. He was joined on Occam’s board by David Whittaker and Brian Dixon.